3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
83
Phase 3
29
Phase 1/2
21
Phase 1
15
Phase 4
7
Phase NA
3
Phase 2/3
3
Status
Completed
6
Active not recruiting
5
Recruiting
3
Unknown
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Waldenstrom Macroglobulinemia
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Interventions
Cisplatin
22
pembrolizumab
17
Drug Therapy
16
Carboplatin
15
Paclitaxel
12
Gemcitabine
12
Dexamethasone
12
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
venetoclax
8
atezolizumab
8
Pemetrexed
8
Oxaliplatin
8
Docetaxel
8
Specimen Handling
7
Radiotherapy
7
Nivolumab
7
Cyclophosphamide
7
Capecitabine
7
130-nm albumin-bound paclitaxel
7
Methotrexate
6
durvalumab
5
blinatumomab
5
Cytarabine
5
Androgen Antagonists
5
tislelizumab
4
spartalizumab
4
pertuzumab
4
Vincristine
4
Trimethoprim, Sulfamethoxazole Drug Combination
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recruiting
×
Rituximab
×
Clear all
NCT05139017
2026-05-22
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled
NCT05991388
2026-02-20
Glo-BNHL
University of Birmingham
Phase 2/3
Recruiting
210 enrolled
NCT04061512
2024-05-10
RAINBOW
University College, London
Phase 2/3
Recruiting
148 enrolled